The CBA Competition Law and Foreign Investment Review Section’s Reviewable Matters / Unilateral Conduct Committee presents:

Registering for Settlement: Generic and Biosimilars

February 28, 2023 | 12:00 PM to 1:30 PM Eastern
Online (Zoom)

When is a drug patent litigation settlement actually an anti-competitive competitor collaboration? Find out by joining us for a discussion on the ins and outs of drug patent litigation settlement agreements and their impacts on competition.

The panel will discuss past Bureau investigations into patent settlement agreements, their findings, as well as the pros and cons of a formal notification system in Canada. 

Moderator

Kaeleigh Kuzma, Osler Hoskin & Harcourt LLP

Speakers

Dany H. Assaf, Torys LLP

Aaron Gladstone, Competition Bureau

Ben Hackett, Goodmans LLP